Hinova Pharmaceuticals (SHSE:688302) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688302 Hinova Pharmaceuticals Inc SHSE:688302
24 GF Score
Price ¥36.83
! 2 Warning Signs
View Full Analysis

What is Hinova Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

SHSE:688302
24GF Score
Hinova Pharmaceuticals Inc SHSE:688302
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hinova Pharmaceuticals Business Description

Address No. 5 Keyuan South Road, No. 2 and 3, 4th Floor, Building 1, Rongyao Building, High-tech Zone, Sichuan Province, Chengdu, CHN, 610041
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
24GF Score

Get the complete analysis for SHSE:688302

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥36.83
Price